Stromedix

STX-100 Phase 2 Trial in Idiopathic Pulmonary Fibrosis Now Recruiting Patients
GO >

Stromedix Secures Additional $5M in Debt Financing
MORE (PDF) >

Stromedix expands its fibrosis pipeline through in-licensing agreement with UCSF
MORE (PDF) >

Stromedix awarded grant under the Qualifying Therapeutic Discovery Project Program
MORE (PDF) >

STX-100 granted orphan drug status for idiopathic pulmonary fibrosis
MORE (PDF) >

Stromedix secures broad patent coverage for lead program
MORE (PDF) >

Stromedix receives orphan drug designation for STX-100 in chronic allograft nephropathy
MORE (PDF) >

Stromedix raises $25 million in a Series B financing round
MORE (PDF) >

Bio-IT World
GO >

Fierce Biotech
GO >

Mass High Tech
GO >

Xconomy.com
GO >

In Vivo Blog
GO >

BioCentury
GO (PDF) >

Company Fact Sheet
Download our Company Fact Sheet for information on who we are and what we do.
DOWNLOAD (PDF) >

Follow Stromedix on Twitter
GO >

STX-100 is Stromedix's first clinical candidate and is being developed for the treatment of idiopathic pulmonary fibrosis.

	Humanized monoclonal antibody to integrin αvβ6
	Completed phase 1 clinical testing
	Provides localized, injury-specific inhibition of TGF-β activation
	Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease
	Broad therapeutic utility in chronic organ failure, acute organ failure and cancer